As one of the leading manufacturers of medical laboratory diagnostics worldwide, EUROIMMUN stands for innovation.

More than 3500 employees in 17 countries develop, produce and sell test systems to support the diagnosis of diseases, as well as software and automation solutions for optimized performance and evaluation of these tests. Laboratories in over 140 countries use EUROIMMUN products to aid in the diagnosis of autoimmune and infectious diseases as well as allergies, and to perform genetic analyses.

The company was founded in 1987 from the University of Lübeck (Germany). In 2018, US-based PerkinElmer, Inc. became the sole shareholder of EUROIMMUN. In 2023, the two PerkinElmer business divisions “Life Sciences” and “Diagnostics” were converted into the new company Revvity, Inc., which also includes EUROIMMUN.

Revvity, Inc. is a science-based solutions company that leverages innovation in life sciences and diagnostics to help improve lives everywhere. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and from diagnosis to cure.

Revvity’s headquarters are located in Waltham, Massachusetts. With revenues of more than $2.7 billion in 2023 and over 11,000 employees worldwide, Revvity serves customers in pharmaceutical and biotech companies, diagnostic labs, academia, and governments in more than 190 countries. It is included in the S&P 500 Index.

Among the initial pioneering achievements of EUROIMMUN was the development of BIOCHIPs in 1983. Today, the company uses fully-automated BIOCHIP fragmentation and production machines which are designed and produced in-house and are in use world-wide.

Furthermore, the company commands a broad technology base, which it has drawn on to stimulate and promote fundamental new developments in medical laboratory diagnostics. Examples are the molecular biological synthesis of designer antigens, the computer-based immunofluorescence microscopy (CAIFM) and the development of multi-parameter microarrays for the identification of gene polymorphisms and pathogens.